Bone metastases are a frequent complication of cancer, occurring in up to 70 percent of patients with advanced breast or prostate cancer and in approximately 15 to 30 percent of patients with carcinoma of the lung, colon, stomach, bladder, uterus, rectum, thyroid, or kidney . By applying sensitive immunocytochemical and molecular assays, disseminated tumor cells (DTC) in bone marrow (BM) can be detected in 20-40% of cancer patients without any clinical or even histopathological signs of metastasis . Detection of overt bone marrow metastasis in adult patients with solid tumors might change the approach to the patient especially without any symptoms and signs of marrow infiltration as there is evidence, at least from patients with breast  and gastric cancer , even micrometastatic disease in bone marrow is associated with a poor prognosis.